ACOG Issues Guidance on GLP-1 Medicines During Pregnancy and Breastfeeding
New professional guidance addresses the use of weight-management and diabetes medicines during pregnancy and lactation.
The American College of Obstetricians and Gynecologists released guidance addressing GLP-1 receptor agonist use during pregnancy and lactation. The update focuses on medication safety and the need for individualised medical advice for women using these medicines.
MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH
Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute
Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.
GLP-1 receptor agonists are medicines used in the management of type 2 diabetes and, in certain formulations, obesity. They influence appetite, digestion and blood-glucose regulation.
As these medicines become more widely used, questions about their safety during pregnancy and breastfeeding have become increasingly important.
The American College of Obstetricians and Gynecologists published new guidance on 13 November addressing GLP-1 medicine use during pregnancy and lactation.
Medication decisions during pregnancy require careful consideration because a medicine that is suitable for a non-pregnant adult may not have established safety for a developing baby. Women planning pregnancy may also need to discuss the timing of medication changes with their healthcare professionals.
The guidance is relevant to obstetricians, gynaecologists, primary-care doctors and women using GLP-1 medicines for diabetes or weight management.
Women should not independently start, stop or change prescribed medication based on general news reports. Anyone who is pregnant, breastfeeding or planning pregnancy should discuss their treatment with the prescribing clinician and maternity-care team.
Story Photo Gallery
Dr. Arvind Deshmukh
VERIFIEDCardiologist & Electrophysiologist
Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.
Scientific References & Journal Citations
- National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
- Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
- European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.
Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.